ERK/PKM2 Axis Drives Warburg Effect in Arsenic-Exposed Hepatocytes

Study Background and Research Question

Inorganic arsenic, a pervasive environmental pollutant, has been recognized as a human carcinogen by the International Agency for Research on Cancer due to its strong association with liver fibrosis and malignant tumor development. Despite the widespread health burden—affecting over 200 million people globally through contaminated water—the molecular mechanisms underlying arsenic-induced carcinogenesis remain incompletely defined. One hallmark of tumorigenesis is metabolic reprogramming, specifically the Warburg effect, where rapidly dividing cells preferentially utilize glycolysis even in the presence of oxygen. Recent literature has established links between arsenic exposure and altered glucose metabolism, but the upstream regulatory pathways orchestrating these processes are unclear. The reference study (Biological Trace Element Research, 2024) addresses this gap by interrogating the roles of pyruvate kinase M2 (PKM2) and extracellular signal-regulated kinase (ERK) in mediating arsenic-induced metabolic and proliferative changes in human L-02 hepatocytes.

Key Innovation from the Reference Study

The primary innovation of this work lies in demonstrating that the ERK/PKM2 signaling axis functions as a pivotal driver of the Warburg effect and cell proliferation in human hepatocytes upon arsenic exposure. While prior studies have observed upregulation of glycolytic genes and glucose uptake in other cell types following arsenic insult, this study delineates a causative pathway: arsenic activates ERK, which in turn modulates PKM2 activity and localization, ultimately controlling the transcription of GLUT1 and LDHA—key mediators of glucose uptake and lactate production. This mechanistic insight provides a theoretical basis for understanding how chronic arsenic exposure may initiate or promote carcinogenesis via metabolic reprogramming.

Methods and Experimental Design Insights

The investigators employed a multi-pronged approach to dissect the pathway:

• Human L-02 hepatocyte cells were treated with low, physiologically relevant concentrations of arsenic (0.2 and 0.4 μmol/L As³⁺ for 48 hours).
• To perturb glycolytic flux and ERK signaling, cells were co-treated with 2-deoxy-D-glucose (2-DG, a glycolysis inhibitor), U0126 (a selective ERK inhibitor), or subjected to PKM2 knockdown via siRNA or overexpression via plasmid transfection.
• Cell viability and proliferation were quantified using CCK-8 and EdU assays, respectively, while lactic acid production was measured in culture media.
• Glucose uptake was assessed using a 2-NBDG-based fluorescent assay, leveraging the properties of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose as a cellular glucose uptake tracer.
• Protein expression and activation states of PKM2, phospho-PKM2_S37, ERK, phospho-ERK, GLUT1, and LDHA were evaluated by Western blotting; PKM2 subcellular localization was visualized by immunocytochemistry.

This comprehensive experimental framework enabled the authors to interrogate both metabolic and signaling endpoints, as well as their interdependencies.

Core Findings and Why They Matter

Key findings from the study include:

• Arsenic exposure significantly increased L-02 cell viability and proliferation, concurrent with elevated glucose uptake (as measured by 2-NBDG fluorescence) and higher lactate release, reflecting a marked Warburg effect (reference study).
• Arsenic treatment upregulated the expression of PKM2, its phosphorylated form (phospho-PKM2_S37), GLUT1, LDHA, and activated ERK signaling. Immunocytochemistry revealed increased nuclear localization of PKM2, consistent with its role as a transcriptional coactivator for glycolytic genes.
• Pharmacological inhibition of ERK (U0126) or knockdown of PKM2 abrogated arsenic-induced increases in cell proliferation, glucose uptake, and lactic acid production. Specifically, U0126 reduced phospho-PKM2_S37 and downstream glycolytic gene expression, confirming the regulatory hierarchy.

Collectively, these results demonstrate that arsenic-induced metabolic reprogramming and proliferation are contingent on ERK-mediated activation and nuclear translocation of PKM2. The coupling of ERK/PKM2 activity to enhanced GLUT1 and LDHA expression offers a mechanistic rationale for the observed Warburg effect. This advances our understanding of how environmental toxins promote tumorigenic phenotypes at a molecular level and underscores the value of dynamic glucose metabolism assays in toxicological research.

Comparison with Existing Internal Articles

The reference study’s workflow—quantifying glucose uptake using 2-NBDG and dissecting glycolytic regulation—aligns closely with established protocols in translational metabolic research. For example, "Strategic Decoding of Glucose Metabolism: 2-NBDG’s Role in Translational Research" discusses mechanistic and quantitative applications of 2-NBDG in profiling metabolic reprogramming under disease-mimicking conditions, paralleling the arsenic-induced metabolic shifts observed here. Similarly, "2-NBDG for Glucose Metabolism Assays: Protocols and Insights" provides practical troubleshooting and workflow refinements for real-time glucose uptake measurement, which would be directly applicable to the fluorescence microscopy and flow cytometry glucose uptake assays used in the arsenic study. These internal resources support the robustness and reproducibility of 2-NBDG-based assays across diverse cell types and experimental models.

Limitations and Transferability

While the findings provide compelling mechanistic insight, several limitations should be considered:

• The study was conducted exclusively in immortalized human L-02 hepatocyte cells; primary hepatocytes or in vivo models may exhibit distinct regulatory dynamics.
• Arsenic concentrations and exposure durations were selected for experimental tractability and may not fully recapitulate chronic, low-level environmental exposures.
• The analysis focused on major glycolytic regulators and did not explore broader transcriptomic or metabolic networks that could contribute to the observed effects.

Nonetheless, the workflow—including the use of 2-NBDG and targeted pathway perturbations—should be readily transferable to other cell lines, including cancer models and disease-relevant primary cells, to further elucidate the generalizability of the ERK/PKM2-driven Warburg effect.

Protocol Parameters

• Arsenic treatment: 0.2–0.4 μmol/L As³⁺ for 48 hours to induce metabolic and proliferative changes in hepatocytes.
• 2-NBDG uptake assay: 10 μM 2-NBDG incubation for 10 minutes is a typical condition for quantifying glucose uptake, as supported by product information and recent literature.
• Inhibitor controls: Use of 2-DG (glycolysis inhibition) and U0126 (ERK inhibition) to dissect pathway dependencies.
• Protein analysis: Western blotting for PKM2, phospho-PKM2_S37, GLUT1, LDHA, ERK, and phospho-ERK; immunocytochemistry for PKM2 localization.
• Cell viability/proliferation: CCK-8 and EdU incorporation assays.

Researchers should validate these parameters for their specific cell models and instrumentation, as uptake kinetics and optimal dye concentrations may differ.

Research Support Resources

For investigators seeking to replicate or extend this workflow, 2-NBDG (SKU B6035) is a well-characterized fluorescent glucose analog suitable for both flow cytometry and fluorescence microscopy glucose uptake assays. This reagent, offered by APExBIO, has been widely validated in studies of glucose metabolism—including diabetes research and tumor metabolism—and supports sensitive, real-time quantification of cellular glucose uptake. Proper solubility and storage protocols should be followed to ensure experimental consistency. Researchers are encouraged to consult internal guides such as "2-NBDG Fluorescence Assays: Protocols & Troubleshooting in Glucose Metabolism" for workflow optimization and troubleshooting insights relevant to diverse metabolic research contexts.